Galectin Therapeutics (GALT) Interest & Investment Income (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Interest & Investment Income of $36000.0 in Q1 2026, up 44.0% quarter-over-quarter from $25000.0 in Q4 2025, and up 2.86% on a YoY basis from $35000.0 in Q1 2025.
Galectin Therapeutics (GALT) Interest & Investment Income (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $36000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 2.86% year-over-year to $36000.0; the TTM figure through Mar 2026 stood at $126000.0 (down 56.85% YoY), while the FY2025 annual figure was $126000.0, down 62.72% from the prior year.
- Interest & Investment Income was $36000.0 for Q1 2026 at Galectin Therapeutics, up from $25000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $93000.0 in Q3 2024 to a low of $1000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $45882.4 across 5 years, with a median of $39000.0 in 2025.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income soared 4300.0% in 2023, then sank 70.24% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $30000.0 in 2022, then jumped by 146.67% to $74000.0 in 2023, then climbed by 13.51% to $84000.0 in 2024, then tumbled by 70.24% to $25000.0 in 2025, then surged by 44.0% to $36000.0 in 2026.
- The last three Interest & Investment Income figures came in at $36000.0 (Q1 2026), $25000.0 (Q4 2025), and $39000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Sep 30, 2024 | 93,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | 62,000.00 |
| Jun 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 44,000.00 |
| Dec 31, 2022 | 30,000.00 |
| Sep 30, 2022 | 18,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 1,000.00 |